Experimental gene-silencing therapy offers hope for hepatitis B cure

Chronic hepatitis B is a long-lasting condition caused by the hepatitis B virus (HBV) that affects about 240 million people worldwide. Current antiviral treatments are designed to keep the virus under control, but they are not a cure, and medications are usually taken indefinitely.

Researchers led by John Marlowe at genetic medicines company nChroma Bio treated cultures of human liver cells infected with hepatitis B with a genetic package they designed called CRMA-1001. This microscopic delivery vehicle includes a targeting guide RNA to find the viral DNA and instructions for making a gene-silencing protein, all wrapped in protective lipid bubbles.

It is designed to travel directly to the viral DNA and attach chemical tags called methyl groups. These tags act like a mute button, keeping the virus switched off without cutting or altering any underlying DNA.

Sign up for Blog Updates